AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at International Congress on
Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced the presentation ofPhase III data, including efficacy, safety and improvements inpatient-centered outcomes in patients with diabetic peripheralneuropathic (DPN) pain treated with the investigational drug
Zenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptorantagonist and sigma-1...
AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at Second International Congress on
Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced Phase III data on theefficacy, safety and improvements in patient-centered outcomes inpatients with diabetic peripheral neuropathic (DPN) pain treatedwith the investigational drug
Zenvia(TM) (dextromethorphan /quinidine) will be presented in two scientific posters at theSecond Internation...
Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia
Long-Term Safety Data at AAN Annual Meeting
ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced that data on thelong-term safety of the investigational drug
Zenvia(TM)(dextromethorphan / quinidine) and the prevalence of InvoluntaryEmotional Expression Disorder (IEED) were presented today during aposter session at the American Academy of Neurology (AAN) 59thAnnual Meeting in Boston....
Avanir Pharmaceuticals Announces Positive Results of Phase III
Study for Zenvia in Diabetic Neuropathic Pain
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced positive top-lineresults from the company's Phase III clinical trial evaluating theinvestigational drug
Zenvia(TM) (dextromethorphanhydrobromide/quinidine sulfate ("DMQ")), an NMDA antagonist andsigma-1 agonist, in diabetic neuropathic pain. The primary endpoint of the trial was based...